Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis
- Bo Zhang
- Runbo Zhong
- Chunlei Shi
- Tianqing Chu
- Wei Zhang
- Huimin Wang
- Xin Gan
- Zhihong Zhang
- Changbin Zhu
- Xing Li
- Wenzhong Su
- Juan Li
- Yanwei Zhang
- Baohui Han
- Hua Zhong
2026-05-25